Bajaj Healthcare Limited (BAJAJHCARE) — Announcement | 26 June 2026

StockFin.ai

Try Free

Bajaj Healthcare announced it is India's first company to receive Central Drugs Standard Control Organisation's Subject Expert Committee recommendation for manufacturing and marketing Cenobamate Tablets across six strengths. This regulatory milestone enables entry into the epilepsy treatment market with a next-generation antiseizure medication. The company highlighted its focus on specialty CNS therapies and global operations serving Europe, USA, and other regions. No financial figures or quantitative impacts were disclosed in the filing.

📄 View Original Announcement (PDF)

📊 Stock Analysis — BAJAJHCARE ✨ Ask AI About This

About Bajaj Healthcare Limited (BAJAJHCARE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹956.52 Cr P/E: 44.9

View full BAJAJHCARE stock details →

📡 Get AI alerts when BAJAJHCARE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track BAJAJHCARE — Free

💡 Ask AI about this filing

"How does this announcement affect Bajaj Healthcare Limited's outlook?" "What did Bajaj Healthcare Limited announce on 26 June 2026?" "Is this positive or negative for BAJAJHCARE?"

Ask AI Free →

📊 More BAJAJHCARE filings

See all BAJAJHCARE filings →

🔥 Also filed on 26 June 2026

SAPPHIRE Sapphire Foods India Limited Annual Report PURVA Puravankara Limited Announcement PRIMO Primo Chemicals Limited Announcement RAJSREESUG Rajshree Sugars & Chemicals Limited Annual Report RAJESHEXPO Rajesh Exports Limited Announcement SAPPHIRE Sapphire Foods India Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when BAJAJHCARE files new disclosures

Track BAJAJHCARE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track BAJAJHCARE — Free

Free account · 2 AI queries/day